Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 7Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2

Conditions

Breast Neoplasms 433Carcinoma, Non-Small-Cell Lung 372Neoplasms 326Prostatic Neoplasms 244Leukemia, Myeloid, Acute 231Multiple Myeloma 230Neoplasm Metastasis 215Melanoma 202Lung Neoplasms 178Leukemia 172Lymphoma 170Colorectal Neoplasms 157Pancreatic Neoplasms 151Lymphoma, Non-Hodgkin 150Recurrence 149Ovarian Neoplasms 146Leukemia, Lymphocytic, Chronic, B-Cell 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 131Myelodysplastic Syndromes 121Carcinoma, Renal Cell 121Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Follicular 108Brain Neoplasms 101Squamous Cell Carcinoma of Head and Neck 96Head and Neck Neoplasms 96Glioblastoma 92Urinary Bladder Neoplasms 88Carcinoma, Hepatocellular 80Hodgkin Disease 73Colonic Neoplasms 73

Interventions

pasireotide 1Rosiglitazone 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Has results × Pituitary ACTH Hypersecretion × Clear all
NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Novartis

Phase 2 Terminated
68 enrolled 25 charts
Endocrine

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

NCT00612066 2020-08-06

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Jonsson Comprehensive Cancer Center

Phase 2 Terminated
2 enrolled 5 charts
Endocrine

Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡